Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22924598 | 1.00 | OPRM1 (0.82) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21383308 | 0.92 | OPRM1 (0.89) | OPRM1OPRD1OPRK1 | |
| SCHEMBL27304360 | 0.90 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 | |
| SCHEMBL22924607 | 0.90 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 | |
| SCHEMBL22924610 | 0.90 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 | |
| SCHEMBL22924604 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21383227 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 | |
| SCHEMBL32663820 | 0.88 | OPRM1 (0.75) | OPRM1OPRD1OPRK1 | |
| SCHEMBL32663798 | 0.88 | OPRM1 (0.75) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21399568 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768679-B1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | US HEALTH (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11352365-B2 | Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210024532-A1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-28 | — | — | US | disclosed |
| EP-3768679-A1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019182950-A1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024532-A1 | BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 2/4885 |
| US-11352365-B2 | Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.